Highlights in nanocarriers for the treatment against cervical cancer

- Uterine cancer is the abnormal growth of cells that comprise uterine tissue.
- Conventional treatments show side effects and non-specifically for tumor cells.
- New alternatives appointing delivery of chemotherapeutic agents by nanocarriers
- Use of nanocarriers allows targeting to the tissue tumor.
- Nanotechnology-based vaccines show a potential prevention of HPV, which cause of cervical cancer.

Cervical cancer is the second most common malignant tumor in women worldwide and has a high mortality rate, especially when it is associated with human papillomavirus (HPV). In US, an estimated 12,820 cases of invasive cervical cancer and an estimated 4210 deaths from this cancer will occur in 2017. With rare and very aggressive conventional treatments, one sees in the real need of new alternatives of therapy as the delivery of chemotherapeutic agents by nanocarriers using nanotechnology. This review covers different drug delivery systems applied in the treatment of cervical cancer, such as solid lipid nanoparticles (SNLs), liposomes, nanoemulsions and polymeric nanoparticles (PNPs). The main advantages of drug delivery thus improving pharmacological activity, improving solubility, bioavailability to bioavailability reducing toxicity in the target tissue by targeting of ligands, thus facilitating new innovative therapeutic technologies in a too much needed area. Among the main disadvantage is the still high cost of production of these nanocarriers. Therefore, the aim this paper is review the nanotechnology based drug delivery systems in the treatment of cervical cancer.

73